Compare DK & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DK | ELVN |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2017 | 2020 |
| Metric | DK | ELVN |
|---|---|---|
| Price | $40.32 | $43.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 5 |
| Target Price | $38.88 | ★ $43.40 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | ★ 95.67 | 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.85 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.80 | $14.79 |
| 52 Week High | $48.32 | $48.53 |
| Indicator | DK | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 58.43 |
| Support Level | $36.34 | $16.84 |
| Resistance Level | $40.55 | $48.53 |
| Average True Range (ATR) | 1.97 | 2.42 |
| MACD | -0.43 | -0.50 |
| Stochastic Oscillator | 35.05 | 47.59 |
Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. It has three segments: Refining segment and Logistics segment and retail segment. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.